Tissue Repair Announces USA Patent Approval
Filed with ASX · · 1 page · English
Earlier from Tissue Repair
- Appendix 4D and Half Year Report to 31 December 2021
- Tissue Repair Progresses TR-987 towards Phase III
Later from Tissue Repair
- Lodgement of Type C Meeting Request with US FDA
- Appendix 4E and Annual Report 30 June 2022
- Second US Patent granted for Glucoprime
- FDA Response Clarifies Path to Phase 3 Trials
- TR Pro accepted for peer reviewed journal publication
Follow Tissue Repair into a list and get an email when it puts out news.
Follow Tissue Repair